Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of AJU-G721 and G721R in Healthy Adult Male Subjects
NCT07643233Phase 1Not yet recruiting
- Sponsor
- AJU PHARM Co., Ltd.
- Start
- Jul 2026
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in benign prostatic hyperplasia (BPH) (2 arms), sponsored by AJU PHARM Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration at 48 hours and Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at 48 hours. Planned start Jul 2026; status: not yet recruiting.
02
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT07643233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07643233.